European Union - English - EMA (European Medicines Agency)

virbac s.a. - purified rp-45 felv-envelope antigen - inactivated viral vaccines - cats - active immunisation of cats from eight weeks of age against feline leukaemia for the prevention of persistent viraemia and clinical signs of the related disease.

European Union - English - EMA (European Medicines Agency)

virbac s.a. - purified p45 feline leukaemia virus envelope antigen, live feline calicivirus (strain f9), live feline viral rhinotracheitis virus (strain f2), live feline panleucopenia virus - live feline panleucopenia virus / parvovirus + live feline rhinotracheitis virus + live feline calicivirus + inactivated feline leukaemia virus - cats - for active immunisation of cats from eight weeks of age against:feline calicivirosis to reduce clinical signs.feline viral rhinotracheitis to reduce clinical signs and viral excretion.feline panleucopenia to prevent leucopenia and to reduce clinical signs.feline leukaemia to prevent persistent viraemia and clinical signs of the related disease.onset of immunity: 3 weeks after the primary vaccination for the panleucopenia and leukaemia components, and 4 weeks after the primary vaccination for the calicivirus and rhinotracheitis virus components.duration of immunity: one year after the primary vaccination for all components.

European Union - English - EMA (European Medicines Agency)

virbac s.a. - purified p45 felv-envelope antigen - inactivated viral vaccines, feline leukaemia virus, immunologicals for felidae, - cats - active immunisation of cats from eight weeks of age against feline leukaemia for the prevention of persistent viraemia and clinical signs of the related disease.

United States - English - NLM (National Library of Medicine)

sanofi pasteur inc. - tuberculin purified protein derivative (unii: i7l8fkn87j) (tuberculin purified protein derivative - unii:i7l8fkn87j) - tuberculin purified protein derivative 5 [iu] in 0.1 ml - tubersol tuberculin purified protein derivative (mantoux), is indicated to aid diagnosis of tuberculosis infection (tb) in persons at increased risk of developing active disease. the centers for disease control and prevention (cdc) have published guidelines regarding populations that would benefit from tuberculin skin testing (tst). current recommendations can be accessed at: http://www.cdc.gov/tb/publications/factsheets/testing.htm. previous bcg vaccination is not a contraindication to tuberculin testing. the skin-test results of bcg vaccinated persons can be used to support or exclude the diagnosis of tb infection. however, an fda-approved interferon gamma release assay is preferred over tuberculin skin test for persons 5 years of age and older who were previously vaccinated with bcg. (8) allergy to any component of tubersol or an anaphylactic or other allergic reaction to a previous test of tuberculin ppd is a contraindication to the use of tubersol. (see description and how supplied.) tubersol should not be administered to: - persons who have had a severe reaction (e.g., necrosis, blistering, anaphylactic shock, or ulcerations) to a previous tst, - persons with documented active tuberculosis or a clear history of treatment for tb infection or disease, (9) - persons with extensive burns or eczema.

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - tuberculin purified protein derivative (unii: i7l8fkn87j) (tuberculin purified protein derivative - unii:i7l8fkn87j) - tuberculin purified protein derivative 5 [iu] in 0.1 ml - tubersol, tuberculin purified protein derivative (mantoux), is indicated to aid diagnosis of tuberculosis infection (tb) in persons at increased risk of developing active disease. the centers for disease control and prevention (cdc) have published guidelines regarding populations that would benefit from tuberculin skin testing (tst). current recommendations can be accessed at: http://www.cdc.gov/tb/publications/factsheets/testing.htm. previous bcg vaccination is not a contraindication to tuberculin testing. the skin-test results of bcg vaccinated persons can be used to support or exclude the diagnosis of tb infection. however, an fda-approved interferon gamma release assay is preferred over tuberculin skin test for persons 5 years of age and older who were previously vaccinated with bcg. (9) allergy to any component of tubersol or an anaphylactic or other allergic reaction to a previous test of tuberculin ppd is a contraindication to the use of tubersol. (see description and how supplied) tubersol should not

United States - English - NLM (National Library of Medicine)

2359 us inc - purified water - purified water------------vaginal irrigation vaginal douche for disinfection. ph balance, and skin barrier. relieves minor vaginal like itching or soreness.

United States - English - NLM (National Library of Medicine)

a-s medication solutions - tuberculin purified protein derivative (unii: i7l8fkn87j) (tuberculin purified protein derivative - unii:i7l8fkn87j) - tuberculin purified protein derivative 5 [iu] in 0.1 ml - tubersol tuberculin purified protein derivative (mantoux), is indicated to aid diagnosis of tuberculosis infection (tb) in persons at increased risk of developing active disease. the centers for disease control and prevention (cdc) have published guidelines regarding populations that would benefit from tuberculin skin testing (tst). current recommendations can be accessed at: http://www.cdc.gov/tb/publications/factsheets/testing.htm. previous bcg vaccination is not a contraindication to tuberculin testing. the skin-test results of bcg vaccinated persons can be used to support or exclude the diagnosis of tb infection. however, an fda-approved interferon gamma release assay is preferred over tuberculin skin test for persons 5 years of age and older who were previously vaccinated with bcg. (8) allergy to any component of tubersol or an anaphylactic or other allergic reaction to a previous test of tuberculin ppd is a contraindication to the use of tubersol. (see description and how supplied.) tubersol should not

Philippines - English - FDA (Food And Drug Administration)

quinosil laboratory inc. - purified water (distilled water) - distilled water

Australia - English - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - pneumococcal purified capsular polysaccharides, quantity: 50 microgram/ml - injection, solution - excipient ingredients: water for injections; phenol; sodium chloride - pneumovax 23 is indicated for immunisation of individuals in the following situations: all individuals over the age of 65 years; individuals with asplenia, either functional or anatomical, including sickle cell disease, in persons more than 2 years of age; where possible the vaccine should be given at least 14 days before splenectomy; immunocompromised patients at increased risk of pneumococcal disease (eg patients with hiv infection before the development of aids, nephrotic syndrome, multiple myeloma, lymphoma, hodgkin's disease and organ transplantation); aboriginal and torres strait islander people over 50 years of age; immunocompetent persons at increased risk of complications from pneumococcal disease because of chronic illness (eg chronic cardiac, renal or pulmonary disease, diabetes mellitus, alcoholism and cirrhosis); patients with cerebrospinal fluid leaks. in australia, the national health and medical research council (nhmrc) currently recommends the vaccination of tobacco smokers with the 23-valent polysaccharide pneumococcal vaccine. pneumovax 23 is indicated for immunisation only against pneumococcal disease caused by those pneumococcal types included in the vaccine. effectiveness of the vaccine in the prevention of pneumococcal pneumonia and pneumococcal bacteremia has been demonstrated. in australia, the national health and medical research council (nhmrc) currently recommeds the vaccination of tabacco smokers with the 23-valent polysaccharide pneumococcal vaccine. pneumovax 23 will not prevent disease caused by capsular types of pneumococcus othar those contained in the vaccine.

Canada - English - Health Canada

aventis pasteur limited - purified protein derivative battey bacillus - liquid - 0.5mcg - purified protein derivative battey bacillus 0.5mcg - urine and feces contents